The first-in-class oral RIPTAC molecule JNJ-6143 reached a 75% overall response rate and significant declines in PSA in ...
Real-world study shows outpatient tarlatamab for relapsed SCLC is feasible, with mostly low-grade CRS, rare ICANS, low ICU ...
Daniel Heng, MD, MPH, FRCPC, discusses LITESPARK-011 and LITESPARK-012 data defining belzutifan's role in second-line and later advanced RCC.
Niu, MD, reviews first-line treatment options for EGFR-mutant metastatic non–small cell lung cancer (NSCLC), noting that osimertinib monotherapy was the preferred first-line therapy based on the ...
The IMpactMF trial was discontinued after an independent committee determined imetelstat was unlikely to improve overall ...
Five-year OLYMPUS data show Jelmyto (UGN-101) sustains kidney-sparing control in low-grade UTUC, with most responders ...
ADCs improved on chemotherapy-based regimens in PD-L1–negative and EGFR-mutated NSCLC, while chemotherapy plus pembrolizumab ...
Bhavana Pothuri, MD, discusses TroFuse-005 at ESMO 2026, including TROP2 expression, treatment sequencing, and the future of ...
Bhavana Pothuri, MD, discusses phase 3 TroFuse-005 data from ESMO, where sac-TMT improved PFS and OS vs chemotherapy in ...
Jacob Sands, MD, discusses the top findings from the phase 3 DeLLphi-305 study evaluating tarlatamab and durvalumab as ...
Paul L. Swiecicki, MD, of the University of Michigan Rogel Cancer Center, addresses whether biomarker testing is needed to ...
Five phase 3 analyses presented as late-breaking abstracts at the 2026 European Society for Medical Oncology (ESMO) Congress ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results